SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $50.9 million in its first quarter. On a per-share basis, the San Francisco-based company ...

Good day and thank you for standing by. Welcome to the Nectar Therapeutics first quarter 2025 Financial results conference call. Thank you, Crystal, and good afternoon, everyone. Thank you for ...

Nektar Therapeutics (NKTR) reported a disappointing financial performance for Q1 2025, missing both earnings and revenue forecasts. The company posted an EPS of -$0.24 against a forecast of -$0.16 ...

Nektar Therapeutics (NASDAQ:NKTR) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Nektar ...

(RTTNews) - Nektar Therapeutics (NKTR) released Loss for its first quarter that increased from last year and missed the Street estimates. The company's bottom line came in at -$50.88 million ...

Silva Devarj was living in Boston and her then-boyfriend Shanoor was living in Chicago. The couple started exchanging hand-painted greeting cards they made themselves. "I would send him loving ...

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Nivolumab plus relatlimab ...

We will share our thoughts when the time comes.” Former Turkish referee Ahmet Cakar does not think that Osimhen will be at Galatasaray next season. Cakar told the Turkish media: “In my opinion ...

Rob Lynch, when he joined Shake Shack last May, stepped right to the doorstep of a transformational year. In January, Lynch laid out the wide, long-term view—quadruple the corporate footprint to 1,500 ...

Burger King is giving Guests fun and flavor this May with mouthwatering deals you cannot miss. *Valid 5/4/2025 at part. U.S. rest. on the BK App or bk.com for order ...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.